2025 North America Antibodies Contract Manufacturing Revenue Opportunities Report
Description
The 2025 North America Antibodies Contract Manufacturing Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in antibody contract manufacturing in North America are AGC Biologics, Emergent BioSolutions, Fujifilm Diosynth Biotechnologies, and KBI Biopharma. AGC Biologics, headquartered in the US, offers comprehensive services from cell line development to antibody drug manufacturing and recently expanded its mammalian bioreactor capacity in Copenhagen. Emergent BioSolutions specializes in biologics manufacturing with a strong presence in North America supporting various therapeutic antibodies. Fujifilm Diosynth Biotechnologies is notable for advanced biologics development and manufacturing capabilities, including antibody therapeutics. KBI Biopharma focuses on complex biologic drug manufacturing and development services in the antibody space.
These firms benefit from North America capturing about 55% of the global antibody CMO market due to heavy investments in biopharma R&D and multiple facility expansions across the US. Major drivers include high monoclonal antibody demand, robust regulatory support, and innovation in mammalian cell culture systems. Other key players globally include Lonza, Samsung Biologics, and Thermo Fisher Scientific, but the four listed are especially prominent in the North American antibody CMO sector. North America’s leadership is underpinned by advanced infrastructure, skilled workforce, and strategic collaborations aimed at enhancing biologic manufacturing capacity.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in antibody contract manufacturing in North America are AGC Biologics, Emergent BioSolutions, Fujifilm Diosynth Biotechnologies, and KBI Biopharma. AGC Biologics, headquartered in the US, offers comprehensive services from cell line development to antibody drug manufacturing and recently expanded its mammalian bioreactor capacity in Copenhagen. Emergent BioSolutions specializes in biologics manufacturing with a strong presence in North America supporting various therapeutic antibodies. Fujifilm Diosynth Biotechnologies is notable for advanced biologics development and manufacturing capabilities, including antibody therapeutics. KBI Biopharma focuses on complex biologic drug manufacturing and development services in the antibody space.
These firms benefit from North America capturing about 55% of the global antibody CMO market due to heavy investments in biopharma R&D and multiple facility expansions across the US. Major drivers include high monoclonal antibody demand, robust regulatory support, and innovation in mammalian cell culture systems. Other key players globally include Lonza, Samsung Biologics, and Thermo Fisher Scientific, but the four listed are especially prominent in the North American antibody CMO sector. North America’s leadership is underpinned by advanced infrastructure, skilled workforce, and strategic collaborations aimed at enhancing biologic manufacturing capacity.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
